Loading...
•
Dec 31, 2024
Azenta Q1 2025 Earnings Report
Reported a strong start to fiscal year 2025 with positive momentum in demand for Sample Management Solutions and Multiomics services.
Key Takeaways
Azenta reported a 4% year-over-year increase in revenue to $148 million, driven by growth in both Sample Management Solutions and Multiomics. The company's adjusted EBITDA margin improved by 400 basis points year-over-year to 9.0%, and non-GAAP diluted EPS remained flat at $0.08.
Revenue increased by 4% year-over-year to $148 million.
Sample Management Solutions revenue grew by 3% year-over-year to $81 million.
Multiomics revenue increased by 6% year-over-year to $66 million.
Adjusted EBITDA margin improved by 400 basis points to 9.0%.
Azenta
Azenta
Azenta Revenue by Segment
Revenue by Segment
Sample Management Solutions Revenue
CapyFin.comMultiomics Revenue
CapyFin.com Forward Guidance
The Company is reiterating its revenue guidance for fiscal year 2025.
Positive Outlook
- Total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024.
- Adjusted EBITDA margin expansion is expected to be approximately 300 basis points relative to fiscal 2024.
- Focus on cost reduction
- Focus on productivity improvement
- Simplifying, standardizing, streamlining, and optimizing the Company’s operations, processes and systems to permanently alter the Company’s operations for the long term.
Challenges Ahead
- Volatility of the life sciences markets the Company serves.
- Possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality.
- The inability of customers to make payments to us when due.
- Price competition.
- Disputes concerning intellectual property.
Revenue & Expenses
Visualization of income flow from segment revenue to net income